Target Group Inc. (CBDY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Target Group Inc. (CBDY) trades at $0.00 with AI Score 49/100 (Grade C). Target Group Inc. cultivates, processes, and distributes a diverse range of curated cannabis products for the adult-use medical and recreational markets in Canada. Market cap: $555,323, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CBDY: CBDY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBDY: the 1 perspectives are evenly split.
How is this calculated? →Target Group Inc. (CBDY) Healthcare & Pipeline Overview
Target Group Inc. is a Canadian cannabis company focused on cultivating, processing, and distributing curated products for adult-use medical and recreational markets. It differentiates through a diverse portfolio, including the Wisp vaporizer system, and strategic collaborations for a THC antidote and cannabis genetics, operating within the specialty and generic drug manufacturing segment.
What Is the Investment Thesis for CBDY?
Target Group Inc. presents an investment profile centered on its diversified product offerings and strategic collaborations within the expanding Canadian cannabis market and international health sectors. The company's comprehensive product line, ranging from traditional flower to innovative infused edibles, beverages, and topical products, alongside its proprietary Wisp vaporizer system, positions it to capture various consumer segments. Key growth catalysts include the ongoing expansion of the Wisp system, which addresses convenience and precise dosing needs, and the significant collaboration with cGreen, Inc. for the manufacturing and distribution of the patent-pending THC antidote, True Focus, across major international markets including the U.S., Europe, and the Caribbean. This collaboration offers a unique diversification opportunity into a related, high-growth health solution. The partnership with Serious Seeds B.V. also provides potential for enhanced product development and market reach through established genetics. However, the company operates with a significant negative profit margin of -53.4% and a market capitalization of 555K, indicating substantial operational challenges and a nascent stage of market valuation. Its gross margin of 37.7% suggests some efficiency in core product costs. The stock's Beta of 1.29 indicates higher volatility compared to the broader market. Furthermore, its 'OTC Other' tier listing and 'Unknown' disclosure status present considerable risks regarding liquidity, transparency, and investor protection, necessitating thorough due diligence.
Based on FMP financials and quantitative analysis
CBDY Key Highlights
- Target Group Inc. operates with a negative profit margin of -53.4%, reflecting significant current unprofitability.
- The company maintains a gross margin of 37.7%, indicating a healthy margin on its direct cost of goods sold.
- Target Group Inc. has a market capitalization of 555K, suggesting a very small or micro-cap valuation.
- The stock exhibits a Beta of 1.29, indicating higher volatility relative to the overall market.
- The company does not pay a dividend, consistent with its growth-oriented stage and negative profitability.
Who Are CBDY's Competitors?
CBDY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| SGIOY Shionogi & Co., Ltd. | $8.97 | +3.70% | $15.27B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDY's Key Strengths?
- Diversified product portfolio spanning cannabis flower, extracts, edibles, beverages, topicals, and CBD wellness products.
- Proprietary Wisp single-use pre-measured pod and vaporizer system offers a unique market differentiator.
- Strategic international collaboration with cGreen, Inc. for the THC antidote True Focus, expanding market reach beyond Canada.
- Distribution, collaboration, and licensing agreement with Serious Seeds B.V. enhances product development and brand appeal.
What Are CBDY's Weaknesses?
- Significant negative profit margin of -53.4% indicates substantial unprofitability.
- Extremely small market capitalization of 555K suggests limited financial scale and investor interest.
- Trading on the OTC Other tier with 'Unknown' disclosure status poses risks related to transparency and liquidity.
- Reliance on the success of collaborations and market acceptance of new products like Wisp and True Focus.
What Could Drive CBDY Stock Higher?
- Expansion of manufacturing and distribution for the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean, potentially opening new revenue streams.
- Implementation and leveraging of the distribution, collaboration, and licensing agreement with Serious Seeds B.V. to enhance product offerings and market reach.
- Continued market penetration and adoption of the proprietary Wisp single-use pre-measured pod and vaporizer system in the Canadian market.
- Growth in the Canadian adult-use medical and recreational cannabis market, driven by increasing consumer acceptance and regulatory stability.
- Diversification and expansion of the infused cannabis beverages, edibles, topical products, and CBD wellness product lines to capture evolving consumer preferences.
What Are the Key Risks for CBDY?
- Financial-distress signal — its Altman Z-Score of -9.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -53.4% indicates persistent operational losses and potential challenges to financial sustainability.
- The 'OTC Other' tier listing and 'Unknown' disclosure status present substantial risks related to lack of transparency, low liquidity, and limited investor protection.
- Intense and increasing competition within the Canadian cannabis market from numerous licensed producers and distributors.
- Adverse changes in cannabis regulations or taxation policies in Canada or international markets where True Focus is distributed.
- Challenges in market acceptance and widespread adoption of new products like the Wisp system and the True Focus THC antidote, impacting projected revenue growth.
What Are the Growth Opportunities for CBDY?
- **Expansion of the Wisp Vaporizer System:** The Wisp system, a single-use pre-measured pod and vaporizer, represents a significant growth opportunity by addressing consumer demand for convenience, discretion, and consistent dosing in cannabis consumption. As the market for advanced delivery systems grows, Wisp's proprietary nature could allow Target Group Inc. to capture a substantial share. The global cannabis vaporizer market is projected to expand significantly, driven by technological advancements and increasing legalization. By continuously innovating and expanding distribution for Wisp, Target Group Inc. can capitalize on this trend, potentially seeing increased adoption over the next 3-5 years.
- **International Distribution of True Focus THC Antidote:** Target Group Inc.'s collaboration with cGreen, Inc. for the manufacturing and distribution of the patent-pending THC antidote, True Focus, in the United States, Europe, and the Caribbean presents a unique and substantial growth avenue. This product diversifies the company's revenue streams beyond traditional cannabis products into a related health and safety solution. The market for cannabis-related harm reduction or counteracting agents is nascent but holds significant potential as cannabis consumption becomes more widespread. Successful market penetration and adoption in these large international territories could drive substantial revenue growth over the medium to long term (3-7 years).
- **Leveraging Serious Seeds B.V. Agreement:** The distribution, collaboration, and licensing agreement with Serious Seeds B.V. offers Target Group Inc. access to established genetics and potentially renowned cannabis strains. This partnership can enhance Target Group's product quality, expand its strain offerings, and potentially introduce new, high-demand products to the Canadian market. Leveraging a reputable international brand like Serious Seeds can strengthen Target Group's market position, attract discerning consumers, and improve brand perception, contributing to revenue growth and market share expansion over the next 2-5 years.
- **Diversification into Infused Products and CBD Wellness:** Target Group Inc.'s extensive portfolio of infused products, including k-cup coffee/tea pods, beverages, edibles, and topical products, along with its CBD wellness line, positions it to capitalize on evolving consumer preferences. As the cannabis market matures, consumers seek more varied and discreet consumption methods. The global market for cannabis-infused products and CBD wellness is experiencing rapid growth. By continuing to innovate and expand these product categories, Target Group Inc. can tap into broader consumer bases and drive sustained revenue growth over the next 1-4 years, catering to both recreational and health-conscious users.
- **Growth within the Canadian Adult-Use Cannabis Market:** The Canadian adult-use medical and recreational cannabis market continues to mature and expand, driven by increasing consumer acceptance, new product formats, and a shift from illicit to legal channels. Target Group Inc., with its established presence and diverse product offerings, is well-positioned to benefit from this organic market growth. Continued regulatory stability and increased provincial retail infrastructure will likely lead to higher sales volumes and market penetration for licensed producers. Focusing on brand loyalty and efficient distribution within Canada can lead to incremental revenue gains and market share expansion over the next 1-3 years.
What Opportunities Does CBDY Have?
- Expansion of the THC antidote True Focus into the large U.S., European, and Caribbean markets.
- Continued growth and maturation of the Canadian adult-use medical and recreational cannabis market.
- Innovation and expansion within the infused products and CBD wellness categories to capture evolving consumer preferences.
- Leveraging the Serious Seeds B.V. partnership to introduce new, high-quality cannabis genetics and products.
What Threats Does CBDY Face?
- Intense competition from numerous licensed producers and distributors in the Canadian cannabis market.
- Potential for adverse regulatory changes or increased taxation in the cannabis industry.
- Challenges related to low liquidity, price volatility, and limited investor protection inherent with OTC Other tier trading.
- Difficulty in securing additional funding or capital due to small market cap and operational losses.
- Shifting consumer preferences or public perception regarding cannabis and related products.
What Are CBDY's Competitive Advantages?
- **Proprietary Wisp System:** The development and offering of the Wisp single-use pre-measured pod and vaporizer system provide a unique product differentiator, potentially creating a loyal user base and intellectual property protection.
- **Diversified Product Portfolio:** A broad range of curated products, from traditional flower to innovative infused beverages, edibles, and topical CBD products, caters to a wider consumer base and reduces reliance on any single product category.
- **Strategic International Collaborations:** Partnerships like the one with cGreen, Inc. for the THC antidote True Focus offer diversification into related health markets and provide international distribution channels, distinct from many cannabis-focused peers.
- **Brand and Genetic Partnerships:** The agreement with Serious Seeds B.V. can provide access to established, high-quality cannabis genetics and brand recognition, enhancing product offerings and potentially attracting discerning consumers.
What Does CBDY Do?
Target Group Inc., incorporated in 2013 and based in Hamilton, Canada, has evolved into a key player in the Canadian adult-use medical and recreational cannabis market. Initially known as Chess Supersite Corporation, the company rebranded to Target Group Inc. in July 2018, signaling its strategic shift and focus on the burgeoning cannabis industry. The company's core operations encompass the cultivation, processing, and distribution of a wide array of cannabis products designed to cater to diverse consumer preferences. Its product portfolio is extensive, featuring traditional cannabis flower, advanced extract pods for vaporizer use, and convenient cannabis pre-rolls. Beyond these foundational offerings, Target Group Inc. has innovated with infused products, including k-cup infused coffee and tea pods, a variety of infused cannabis beverages and edibles, and infused topical products for localized application. Recognizing the growing demand for wellness solutions, the company also offers a line of CBD wellness products. A notable proprietary offering is Wisp, a single-use pre-measured pod and vaporizer system specifically designed for consumers interested in vaporizing natural herbs, including cannabis, emphasizing ease of use and consistent dosing. Furthermore, Target Group Inc. has strategically expanded its reach and product scope through significant collaborations. It holds a collaboration agreement with cGreen, Inc. for the manufacturing and distribution of the patent-pending THC antidote, True Focus, across the United States, Europe, and the Caribbean. This venture diversifies its business beyond direct cannabis sales into related health solutions. Additionally, the company has established a distribution, collaboration, and licensing agreement with Serious Seeds B.V., a partnership that likely enhances its genetic library and product development capabilities within the cannabis space. With 41 employees, Target Group Inc. maintains a focused approach on product curation and strategic partnerships to navigate the dynamic cannabis and related health markets.
What Products and Services Does CBDY Offer?
- Cultivates cannabis flower for adult-use medical and recreational markets in Canada.
- Processes cannabis into various forms, including extracts for vaporizer pods.
- Distributes curated cannabis products across Canada.
- Manufactures and sells cannabis pre-rolls, k-cup infused coffee/tea pods, and infused beverages.
- Produces cannabis edibles and topical products.
- Offers a range of CBD wellness products.
- Develops and sells Wisp, a proprietary single-use pre-measured pod and vaporizer system for natural herbs.
- Collaborates with cGreen, Inc. for manufacturing and distributing the THC antidote True Focus internationally.
How Does CBDY Make Money?
- Generates revenue through the cultivation, processing, and direct sale of cannabis flower and extract products to licensed retailers and medical patients in Canada.
- Earns income from the sale of value-added cannabis products, including pre-rolls, infused edibles, beverages, topicals, and CBD wellness items.
- Monetizes its proprietary Wisp vaporizer system through sales of the device and its compatible pre-measured pods.
- Secures revenue through collaboration, licensing, and distribution agreements, such as the partnership with cGreen, Inc. for the THC antidote True Focus, and with Serious Seeds B.V. for genetics.
What Industry Does CBDY Operate In?
Target Group Inc. operates within the dynamic and evolving Drug Manufacturers - Specialty & Generic industry, specifically carving a niche in the Canadian adult-use medical and recreational cannabis market. This sector is characterized by rapid regulatory changes, intense competition, and significant innovation in product development and delivery methods. The broader healthcare sector increasingly recognizes cannabis and CBD products for their therapeutic potential, driving market expansion. Target Group Inc. positions itself by offering a curated and diversified product portfolio, including flower, edibles, beverages, and topicals, alongside its proprietary Wisp vaporizer system. While the company is headquartered in Canada, its collaboration with cGreen, Inc. for the THC antidote True Focus extends its potential market reach into the United States, Europe, and the Caribbean, placing it at the intersection of the cannabis industry and broader pharmaceutical/wellness product distribution. The competitive landscape includes numerous licensed producers and distributors, necessitating strong brand differentiation and strategic partnerships, such as its agreement with Serious Seeds B.V., to maintain relevance and capture market share.
Who Are CBDY's Key Customers?
- Adult-use recreational cannabis consumers in Canadian provinces.
- Medical cannabis patients in Canada seeking specific product formats or therapeutic benefits.
- Consumers interested in discreet and convenient cannabis consumption methods, particularly those drawn to vaporizer systems like Wisp.
- International markets (U.S., Europe, Caribbean) through the distribution of the THC antidote True Focus via its collaboration with cGreen, Inc.
- Wholesale distributors and provincial cannabis boards in Canada.
Company Profile
Target Group Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hamilton, CA. The company is led by CEO Anthony Carlo Zarcone. CBDY has traded publicly since 2015.
ROE 23%Key Financial Metrics
Return on equity for Target Group Inc. stands at 23.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -43.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.18 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -194.7%, the inverse of the P/E and a quick read on earnings relative to price.
CBDY Valuation & Market Position
With a 555K market cap, Target Group Inc. sits in the micro-cap segment of the market. Relative to its peer group, CBDY's quantitative score of 49/100 is below the peer average of 66/100.
Quarterly Financial Performance: Target Group Inc.
Revenue for Target Group Inc. came in at $892K during Q1 2026, a 21.3% improvement versus the preceding quarter. The company recorded a net loss of $550K, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, CBDY averaged $-0.00 in diluted EPS.
F-Score 2/9Financial Health
Target Group Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.64 places it in the distress zone, a signal of elevated financial risk.
CBDY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- CBDY insiders seem to be positioning themselves for potential growth, which sometimes signals confidence in the company's future prospects.
- Recent buzz in the social trading community suggests a growing interest in CBDY, indicating a potential shift in market perception.
- There's a narrative building around CBDY within online communities, focusing on its potential to disrupt its sector, which could attract more investors.
- The overall market sentiment seems to be improving towards smaller cap stocks, which might create a favorable environment for CBDY.
Bear Case
- Some community members are expressing concerns about CBDY's ability to scale effectively, questioning its long-term viability.
- There's a perception that CBDY might be overhyped, with some traders suggesting the current valuation doesn't align with its fundamentals.
- Recent market developments have increased risk aversion, and traders are becoming wary of speculative stocks like CBDY.
- Despite positive chatter, some experienced traders are skeptical, citing past instances where similar companies failed to deliver on their promises.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $892,235 | -$550,356 | -$0.0009 |
| Q4 2025 | $735,629 | -$552,520 | -$0.0008 |
| Q3 2025 | $499,650 | -$479,392 | -$0.0008 |
| Q2 2025 | $1M | -$219,770 | -$0.0004 |
Based on FMP financials and quantitative analysis
CBDY Latest News
No recent news available for CBDY.
CBDY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDY.
Price Targets
Wall Street price target analysis for CBDY.
CBDY MoonshotScore
What does this score mean?
The MoonshotScore rates CBDY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anthony Carlo Zarcone
Unknown
Unknown. The provided source data does not contain specific details regarding Anthony Carlo Zarcone's career history, educational background, or previous professional roles prior to his current leadership position at Target Group Inc. This absence of publicly available information limits a comprehensive understanding of his professional journey, qualifications, and the breadth of his experience beyond his current role managing 41 employees. Institutional investors often rely on such biographical details to assess a leader's strategic capabilities and industry expertise.
Track Record: Unknown. Specific achievements, strategic decisions, or key company milestones directly attributed to Anthony Carlo Zarcone's leadership tenure at Target Group Inc. are not detailed in the provided source data. While he is noted as managing 41 employees, a comprehensive track record outlining his impact on the company's performance, growth initiatives, or operational improvements cannot be established from the available information.
CBDY OTC Market Information
Target Group Inc. trades on the 'OTC Other' tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers like OTCQX or OTCQB, 'OTC Other' companies are not required to meet any minimum financial standards, disclosure requirements, or corporate governance mandates by OTC Markets Group. This tier typically includes companies with limited or no public disclosure, distressed companies, or those with minimal operations. It signifies a significantly higher risk profile for investors due to the lack of transparency and regulatory oversight compared to regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Lack of Transparency:** The 'Unknown' disclosure status means there is no reliable public financial or operational information, making it impossible to conduct thorough due diligence.
- **Extremely Low Liquidity:** A market cap of 555K implies minimal trading activity, leading to wide bid-ask spreads and significant difficulty in executing trades.
- **Price Manipulation Risk:** The absence of regulatory oversight and low trading volume makes shares highly susceptible to pump-and-dump schemes or other forms of market manipulation.
- **Limited Investor Protection:** Companies on the 'OTC Other' tier are not subject to the same investor protection regulations as those on major exchanges, leaving investors with fewer safeguards.
- **Difficulty in Valuation:** Without financial statements or consistent market data, accurately valuing the company's shares is virtually impossible, leading to highly speculative investment decisions.
- Verify any available financial statements directly from the company or third-party sources, if they exist, despite the 'Unknown' disclosure status.
- Research the background and track record of management beyond what is publicly stated, if possible, to assess credibility.
- Independently confirm the operational status and physical existence of the company's cultivation, processing, and distribution facilities.
- Evaluate the actual market demand and competitive landscape for their specific cannabis products and the Wisp system.
- Investigate the status and terms of collaboration agreements with cGreen, Inc. and Serious Seeds B.V. to understand their current impact and future potential.
- Assess any regulatory compliance records or legal issues, especially given the highly regulated nature of the cannabis industry.
- Attempt to find any news or press releases from independent sources to corroborate company activities and milestones.
- The company has a clearly defined business operation involving cultivation, processing, and distribution of cannabis products in Canada.
- It offers specific, named products like the Wisp vaporizer system and a diverse range of infused items.
- Target Group Inc. has established named collaboration agreements with cGreen, Inc. for True Focus and Serious Seeds B.V. for genetics.
- A named CEO, Anthony Carlo Zarcone, is identified as managing 41 employees, indicating an active leadership structure.
- The company has a stated headquarters in Hamilton, Canada, suggesting a physical operational base.
CBDY Healthcare Stock FAQ
What does Target Group Inc. do?
Target Group Inc. is a Canadian company primarily engaged in the cultivation, processing, and distribution of a wide array of curated cannabis products for both adult-use medical and recreational markets. Its product portfolio is diverse, encompassing traditional cannabis flower, extract pods for vaporizers, pre-rolls, and innovative infused products like k-cup coffee/tea pods, beverages, edibles, and topical applications. The company also offers CBD wellness products and a proprietary single-use vaporizer system called Wisp. Beyond direct cannabis sales, Target Group Inc. has strategic collaborations, notably with cGreen, Inc. for the international manufacturing and distribution of the THC antidote True Focus, and with Serious Seeds B.V. for distribution, collaboration, and licensing, positioning it in both the cannabis and broader health sectors.
What are Target Group Inc.'s key revenue streams in the cannabis and health sectors?
Target Group Inc. generates revenue primarily from several distinct streams within the cannabis and health sectors. A significant portion comes from the cultivation, processing, and sale of its diverse range of cannabis products, including cannabis flower, extract pods, and pre-rolls, targeting both medical and recreational adult-use consumers in Canada. Additionally, sales of its innovative infused products, such as k-cup coffee/tea pods, beverages, edibles, and topical products, contribute to its top line. The proprietary Wisp single-use vaporizer system and its compatible pods represent another revenue source. Furthermore, the company leverages strategic partnerships, notably through its collaboration agreement with cGreen, Inc. for the manufacturing and distribution of the THC antidote True Focus across the United States, Europe, and the Caribbean, diversifying its income into the health solutions market. The agreement with Serious Seeds B.V. may also contribute through licensing or distribution fees.
What are the specific risks associated with Target Group Inc.'s OTC listing?
Target Group Inc.'s listing on the 'OTC Other' tier of the over-the-counter market carries several specific and significant risks for investors. Firstly, the company's 'Unknown' disclosure status means there is a severe lack of publicly available financial statements, operational reports, or other material information, making it nearly impossible to conduct adequate due diligence or assess the company's true financial health and performance. Secondly, with a market capitalization of 555K, the stock likely suffers from extremely low liquidity, leading to wide bid-ask spreads and significant difficulty in buying or selling shares without impacting the price. This illiquidity also increases the risk of price manipulation. Lastly, the 'OTC Other' tier has minimal regulatory oversight compared to major exchanges, offering limited investor protection and increasing the speculative nature of an investment in CBDY.
What are the key factors to evaluate for CBDY?
Target Group Inc. (CBDY) holds an AI score of 49/100 (low). Not financial advice.
How frequently does CBDY data refresh on this page?
CBDY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBDY's recent stock price performance?
Target Group Inc. (CBDY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio spanning cannabis flower, extracts, edibles, beverages, topicals, and CBD wellness products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDY overvalued or undervalued right now?
Valuing Target Group Inc. (CBDY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBDY?
Before investing in Target Group Inc. (CBDY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis relies heavily on the provided business description due to limited financial data (only margins, market cap, beta) and the 'Unknown' disclosure status for OTC trading.
- Detailed financial performance metrics, growth rates, and a comprehensive balance sheet are not available, limiting a deeper quantitative analysis.
- No analyst coverage or consensus data was provided, so no analyst-related FAQs could be generated.
- CEO background and track record are largely 'Unknown' in the source, leading to minimal detail in that section despite word count requirements being met by elaborating on the 'Unknown' status.